# P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release

> **NCT04489134** · PHASE2 · COMPLETED · sponsor: **Rennes University Hospital** · enrollment: 27 (actual)

## Conditions studied

- Pharmacokinetics

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B
- **DRUG:** Treament C
- **DRUG:** Treatment D
- **BIOLOGICAL:** Pharmacocinetik
- **GENETIC:** Genetic
- **OTHER:** Selection visit:

## Key facts

- **NCT ID:** NCT04489134
- **Lead sponsor:** Rennes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-15
- **Primary completion:** 2023-05-16
- **Final completion:** 2023-05-16
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489134, "P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04489134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*